Clinical trials: Donor
Normal Female Volunteers
Study of Survival Duration for Donor Skin Cells in Skin Biopsy Wounds
The goal for this study is to examine the persistence of growth arrested,allogeneic,male-donor keratinocytes and fibroblasts when applied as product HP802-247 to the surface of acute excisional wounds in health female volunteers…
- Trial name
- NCT01190865
- Testing
- HP802-247
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Healthpoint
Blood Donors
Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
This study will evaluate a new blood collection and filtration system that is intended to be used to collect, filter, separate and store red blood cells and, separately, plasma.
- Trial name
- NCT02145507
- Testing
- SOLX (Investigational), AS-3 (Control)
- Where
- 2 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Meningitis, Meningococcal
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
The purpose of this study was to collect large volumes of matched pairs of pre- and post-vaccination sera from healthy subjects who administered GlaxoSmithKline (GSK) Biologicals' vaccine against meningitis- MenACWY vaccine…
- Trial name
- NCT03493919
- Testing
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
- Where
- 6 sites in Australia, Germany
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
Wound Healing, Wound Infection
Trial of exSALT SD7™ Compared to Xeroform® Petrolatum Dressing for the Management of Partial Thickness Donor Sites
This randomized, controlled trial is designed to evaluate split-thickness donor sites treated with exSALT SD7™ compared to donor sites treated with Xeroform®.
- Trial name
- NCT00968994
- Testing
- The exSALT™ SD7 Wound Dressing, Xeroform® Petrolatum Dressing
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Exciton Technologies Inc.
Donor Site Wound
Evaluation of HQ® Matrix Medical Wound Dressing for Healing of Donor Site Wounds
The purpose of the study is to evaluate the safety and effectiveness of HQ® Matrix Medical Wound Dressing for repair of donor site wounds.
- Trial name
- NCT01993030
- Testing
- HQ® Matrix Medical Wound Dressing, Sidaiyi® wound dressing
- Where
- 2 sites in China
- Volunteers
- 71 people
- Sponsor
- Zhejiang Xingyue Biotechnology Co., Ltd.
Skin Transplantation
Post-market Clinical Follow-up Study for a CE Marked Wound Care Product (FibDex®)
FibDex® 2-2022 is a sponsored, post-marketing clinical follow-up (PMCF) study to monitor the clinical performance and safety of the CE marked product nanofibrillar cellulose (NFC) wound dressing, FibDex®, when used according to…
- Trial name
- NCT05666999
- Testing
- FibDex®, Suprathel, Aquacel Foam
- Where
- Finland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- UPM-Kymmene Corporation
Kidney Transplant Rejection
Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants
The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-103 for induction of functional immune tolerance in past recipients of human leukocyte antigen (HLA)-matched, living…
- Trial name
- NCT03606746
- Testing
- MDR-103
- Sponsor
- Medeor Therapeutics, Inc.
Hematologic Malignancies
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
This is an open-label, non-randomized study to evaluate the safety of two planned infusions of BPX-501 T cells after partially mismatched, related (haploidentical) HSCT in adults with hematologic malignancies.
- Trial name
- NCT02487459
- Testing
- BPX-501, AP1903
- Where
- United States
- Sponsor
- Bellicum Pharmaceuticals
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Acute Ebola Virus Disease
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
- Trial name
- NCT02295501
- Testing
- INTERCEPT Plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cerus Corporation
Non-small Cell Lung Cancer
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
- Trial name
- NCT04616209
- Testing
- donor-derived NK cell infusion
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Precision Biotech Taiwan Corp.
Lung Transplantation
Safety and Efficacy Study of Nitric Oxide in Patients Going Through Lung Transplantation
The purpose of this study is to assess the safety and efficacy of inhaled nitric oxide in prevention of lung graft dysfunction due to ischemia-reperfusion
- Trial name
- NCT00570245
- Testing
- Nitric oxide
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Mallinckrodt
Kidney Transplant Rejection
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
The purpose of this study was to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have had an…
- Trial name
- NCT03897205
- Testing
- Imlifidase, Plasma Exchange
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Hansa Biopharma AB
Heart Transplant, Immunosuppression
HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)
This is an unblinded, randomized, controlled, two-arm interventional research study enrolling patients who are undergoing heart transplantation.
- Conditions
- Heart Transplant, Immunosuppression, Allograft
- Trial name
- MOSAIC (NCT05459181)
- Testing
- HeartCare
- Volunteers
- 930 people
- Sponsor
- CareDx
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01656174
- Testing
- Procleix Dengue Virus Assay
- Where
- 2 sites in United States
- Volunteers
- 35,035 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
EBV-induced Lymphomas, EBV-associated Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced…
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Trial name
- NCT01498484
- Testing
- EBV-specific T cells (EBV-CTLs)
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Atara Biotherapeutics
Surgical Wound, Wound
Oasis Donor Site Wounds Post-Market Study
The purpose of this study is to demonstrate the safety and performance of Oasis extracellular matrix (ECM) when used as a treatment for donor site wounds in the United Kingdom.
- Conditions
- Surgical Wound, Wound, Wounds and Injuries, Wound Heal
- Trial name
- NCT04079348
- Testing
- Oasis ECM, standard wound care
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Cook Biotech Incorporated
Renal Transplantation, Graft Rejection
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Trial name
- NCT00089947
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Genzyme, a Sanofi Company
Third Degree Burns, Diabetes
Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts
This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns.
- Trial name
- NCT01715012
- Testing
- ST266, Saline
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion